Neurotrope Inc (NASDAQ:NTRP) has been assigned a consensus broker rating score of 3.00 (Hold) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation. Neurotrope’s rating score has declined by 200% from 90 days ago as a result of various analysts’ ratings changes.
Analysts have set a 1-year consensus price objective of $1.00 for the company and are anticipating that the company will post ($0.32) EPS for the current quarter, according to Zacks. Zacks has also assigned Neurotrope an industry rank of 146 out of 255 based on the ratings given to its competitors.
A number of research analysts have commented on NTRP shares. Janney Montgomery Scott cut Neurotrope from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $13.00 to $1.00 in a research note on Wednesday, September 11th. ValuEngine upgraded Neurotrope from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research cut Neurotrope from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 10th. Finally, Maxim Group cut Neurotrope from a “buy” rating to a “hold” rating in a research note on Monday, September 9th.
Neurotrope stock traded down $0.01 during midday trading on Thursday, reaching $0.65. The stock had a trading volume of 10,808 shares, compared to its average volume of 826,833. The stock’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $5.16. The stock has a market capitalization of $9.11 million, a PE ratio of -0.47 and a beta of 2.17. Neurotrope has a twelve month low of $0.63 and a twelve month high of $8.40.
Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.07. Analysts predict that Neurotrope will post -1.33 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of NTRP. Morgan Stanley increased its position in Neurotrope by 46.7% during the second quarter. Morgan Stanley now owns 20,402 shares of the company’s stock worth $164,000 after buying an additional 6,490 shares during the last quarter. Cannell Peter B & Co. Inc. increased its position in Neurotrope by 7.5% during the second quarter. Cannell Peter B & Co. Inc. now owns 229,481 shares of the company’s stock worth $1,840,000 after buying an additional 16,100 shares in the last quarter. NorthRock Partners LLC increased its position in Neurotrope by 45.5% during the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock worth $834,000 after buying an additional 32,500 shares in the last quarter. BlackRock Inc. increased its position in Neurotrope by 144.3% during the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock worth $482,000 after buying an additional 35,464 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Neurotrope by 21.7% in the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock valued at $2,139,000 after purchasing an additional 47,609 shares during the period. Institutional investors own 15.02% of the company’s stock.
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Get a free copy of the Zacks research report on Neurotrope (NTRP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.